OrbusNeich Announces Schedule of Events at TCT 2017

HONG KONG, October 23, 2017 /PRNewswire/ --

• Program to include late-breaking presentation of REDUCE clinical trial  
• Data on more than 5,000 patients to be presented  

OrbusNeich, a global company specialising in the provision of life-changing vascular solutions, has today announced a schedule of events at the 29^th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, which takes place from October 29 to November 2 2017 in Denver, Colorado.

Among the highlights is a Late-Breaking oral presentation of one year outcomes of the REDUCE study, a randomised trial comparing 3-month versus 12-month DAPT after implantation of a COMBO stent in patients with ACS, which will be presented by Professor Harry Suryapranata during the morning Late-Breaking Clinical Trial Session on Wednesday November 1.    

In addition, First Report Investigations from HARMONEE, a randomized trial comparing a bioabsorbable polymer-based DES (COMBO™) with an abluminal CD34 antibody coating with a durable polymer-based DES in patients with coronary artery disease, will be presented by Dr Mitchell Krucoff on Monday October 30. HARMONEE is a Harmonization By Doing [HBD] proof-of-concept trial conducted under a single protocol in Japan (to support Shonin approval) and in the U.S. (planned to meet feasibility and angiographic follow up requirements).

Other presentations and abstracts that will be presented at the congress include:  

• 1-year clinical outcomes of a randomized trial (RECOVERY) evaluating the safety and efficacy of the COMBO stent versus a polymer-free sirolimus-eluting stent in patients with de novo native coronary artery lesions
• Results from the observational MASCOT post-marketing registry exploring the safety and efficacy of the COMBO stent in an all-comer PCI cohort
• Insights from the REMEDEE Registry incorporating three-year clinical performance of the COMBO stent

OrbusNeich will also host a lunchtime symposium on Tuesday October 31 covering a variety of topics including true healing and restored functional endothelium as well as the latest evidence from the on-going COMBO clinical programme.

The company will also host 'Meet the COMBO Trialists - Dive Deep, Putting It All Together', on Wednesday November 1. Co-chaired by Dr Roxana Mehran and Dr Mitchell Krucoff, the event features an overview of COMBO trials, followed by a panel discussion.

"As one of the world's largest and most important educational meetings focused on interventional cardiovascular medicine, TCT 2017 provides an opportune venue for us to present data from several notable clinical studies having enrolled over 5,000 patients," said Scott Addonizio, Chief Operating Officer, OrbusNeich. "This latest data will add to the extensive body of evidence supporting the COMBO Dual Therapy Stent, the world's first and only dual therapy stent designed to repair vessel injury and regenerate endothelium, fostering natural, TRUE VESSEL HEALING.  OrbusNeich will continue its focus on providing physicians with novel technology designed to assist in improving clinical performance and most importantly optimizing patient care."  

Details of all OrbusNeich events at TCT 2017 can be found at https://www.orbusneich.com/en/general/download-tct-2017-invitation

The Cardiovascular Research Foundation (CRF) is a non-profit research and educational organisation dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific forum of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. Now in its 29^th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit http://www.crf.org and http://www.tctconference.com

About the COMBO Dual Therapy Stent  

COMBO is the world's first and only dual therapy stent designed to repair vessel injury and regenerate endothelium, fostering natural, true vessel healing. It does this by accelerating endothelial coverage and controlling neo-intimal proliferation. This is done through a combination of the proven EPC capture technology and a sirolimus drug elution, delivered from a bioresorbable polymer that is completely degraded within 90 days. OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

About OrbusNeich - Pioneers in life-changing technologies 

OrbusNeich is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products are the world's first dual therapy stents, the COMBO Plus and COMBO Dual Therapy Stents, together with stents and balloons marketed under the names of Azule™, Scoreflex™, Scoreflex™ NC, Sapphire™ II, Sapphire™ II PRO and Sapphire™ II NC, as well as products to treat peripheral artery disease: the Jade™ and Scoreflex™ PTA balloons. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to physicians in more than 60 countries. For more information, visit http://www.OrbusNeich.com

   
Global Media Contact:

Christine Lydon
+44-20-8618-2889
[email protected]

Deborah Woods
+31332541150
[email protected]

SOURCE OrbusNeich